Cipla to acquire two US generics companies for S550m

摘要

Cipla's UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals. The all-cash transaction, subject to certain closing conditions, is valued at US$550m. This acquisition, which is the second landmark acquisition in Cipla's 80-year history, will give the company scale in the US generics market through a wide-ranging product portfolio in CNS, CVS, anti-infectives and diabetes, as well as other value-added generics. InvaGen offers a large capacity manufacturing base in Hauppauge (NY, US) and a skilled US-based R&D organisation, Cipla's first such presence in the country.